Vanguard Group Inc. increased its stake in shares of InVitae Corp (NASDAQ:NVTA) by 9.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,206,266 shares of the medical research company’s stock after buying an additional 107,775 shares during the period. Vanguard Group Inc. owned 2.86% of InVitae Corp worth $13,341,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in NVTA. Wellington Management Group LLP increased its position in shares of InVitae Corp by 0.6% in the first quarter. Wellington Management Group LLP now owns 3,974,227 shares of the medical research company’s stock valued at $43,955,000 after buying an additional 25,100 shares during the period. State Street Corp increased its position in shares of InVitae Corp by 9.4% in the fourth quarter. State Street Corp now owns 338,514 shares of the medical research company’s stock valued at $2,688,000 after buying an additional 29,017 shares during the period. TIAA CREF Investment Management LLC increased its position in shares of InVitae Corp by 32.8% in the first quarter. TIAA CREF Investment Management LLC now owns 121,549 shares of the medical research company’s stock valued at $1,344,000 after buying an additional 30,039 shares during the period. Bank of New York Mellon Corp increased its position in shares of InVitae Corp by 13.9% in the first quarter. Bank of New York Mellon Corp now owns 105,549 shares of the medical research company’s stock valued at $1,167,000 after buying an additional 12,896 shares during the period. Finally, Wells Fargo & Company MN increased its position in shares of InVitae Corp by 129.0% in the first quarter. Wells Fargo & Company MN now owns 53,235 shares of the medical research company’s stock valued at $589,000 after buying an additional 29,991 shares during the period.

Shares of InVitae Corp (NASDAQ:NVTA) traded down 0.31% during trading on Tuesday, reaching $9.76. The company had a trading volume of 30,376 shares. The stock’s market capitalization is $424.99 million. The stock’s 50-day moving average price is $9.63 and its 200-day moving average price is $9.87. InVitae Corp has a 12 month low of $5.76 and a 12 month high of $11.88.

InVitae Corp (NASDAQ:NVTA) last issued its quarterly earnings results on Monday, August 7th. The medical research company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by $0.02. The company had revenue of $14.34 million during the quarter, compared to analyst estimates of $13.31 million. InVitae Corp had a negative net margin of 199.20% and a negative return on equity of 153.27%. The business’s revenue for the quarter was up 157.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.77) EPS. Equities analysts forecast that InVitae Corp will post ($2.35) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/vanguard-group-inc-has-13-34-million-position-in-invitae-corp-nvta/1530060.html.

NVTA has been the topic of several analyst reports. ValuEngine upgraded InVitae Corp from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. BidaskClub upgraded InVitae Corp from a “sell” rating to a “hold” rating in a research note on Thursday, August 3rd. J P Morgan Chase & Co reiterated an “overweight” rating and issued a $15.00 target price (up from $14.00) on shares of InVitae Corp in a research note on Wednesday, August 9th. Finally, Zacks Investment Research upgraded InVitae Corp from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. InVitae Corp presently has a consensus rating of “Hold” and an average price target of $12.94.

InVitae Corp Company Profile

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Institutional Ownership by Quarter for InVitae Corp (NASDAQ:NVTA)

Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.